MEI Pharma Company Profile (NASDAQ:MEIP)

About MEI Pharma (NASDAQ:MEIP)

MEI Pharma logoMEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MEIP
  • CUSIP: N/A
  • Web: www.meipharma.com
Capitalization:
  • Market Cap: $98.55 million
  • Outstanding Shares: 36,772,000
Average Prices:
  • 50 Day Moving Avg: $2.84
  • 200 Day Moving Avg: $2.01
  • 52 Week Range: $1.34 - $3.26
P/E:
  • Trailing P/E Ratio: 78.82
  • Foreward P/E Ratio: -2.18
  • P/E Growth: -1370.00
Sales & Book Value:
  • Annual Revenue: $22.8 million
  • Price / Sales: 4.32
  • Book Value: $1.49 per share
  • Price / Book: 1.80
Profitability:
  • EBIDTA: $1.06 million
  • Return on Equity: 2.57%
  • Return on Assets: 2.20%
Debt:
  • Current Ratio: 11.95%
  • Quick Ratio: 11.95%
Misc:
  • Average Volume: 479,353 shs.
  • Beta: 1.56
  • Short Ratio: 0.64
 

Frequently Asked Questions for MEI Pharma (NASDAQ:MEIP)

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

How were MEI Pharma's earnings last quarter?

MEI Pharma, Inc. (NASDAQ:MEIP) issued its quarterly earnings data on Thursday, May, 4th. The company reported ($0.02) EPS for the quarter, beating the Zacks' consensus estimate of ($0.03) by $0.01. The business earned $4.51 million during the quarter, compared to analyst estimates of $5 million. View MEI Pharma's Earnings History.

Where is MEI Pharma's stock going? Where will MEI Pharma's stock price be in 2017?

2 analysts have issued 1-year price objectives for MEI Pharma's stock. Their predictions range from $6.50 to $7.00. On average, they anticipate MEI Pharma's stock price to reach $6.75 in the next year. View Analyst Ratings for MEI Pharma.

What are analysts saying about MEI Pharma stock?

Here are some recent quotes from research analysts about MEI Pharma stock:

  • 1. According to Zacks Investment Research, "MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego. " (7/20/2017)
  • 2. Cann analysts commented, "MEI Pharma and partner Helsinn presented positive findings at the European Hematology Association (EHA) meeting in Madrid, Spain from a genetic mutation analysis of patients in a phase II clinical study of the investigational drug pracinostat and azacitidine in acute myeloid leukemia (AML). These data were previously presented at ASCO in early June 2017. These data support our outlook that Helsinn could launch Pracinostat for the treatment of AML and other potential indications in calendar Q1 2022. Potential sales will be recognized in the form of royalty income by MEI Pharma." (6/26/2017)

Who are some of MEI Pharma's key competitors?

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the folowing people:

  • Christine Anna White M.D., Independent Chairman of the Board
  • Daniel P. Gold Ph.D., President, Chief Executive Officer, Director
  • Brian G. Drazba, Chief Financial Officer, Secretary
  • David M. Urso, Senior Vice President of Corporate Development, General Counsel
  • Robert D. Mass M.D., Chief Medical Officer
  • Charles V. Baltic III, Independent Director
  • Kevan E. Clemens Ph.D., Independent Director
  • Nicholas R. Glover Ph.D., Independent Director
  • Thomas C. Reynolds M.D. Ph.D., Independent Director
  • William Dodge Rueckert, Independent Director

Who owns MEI Pharma stock?

MEI Pharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.01%), InterWest Venture Management Co (1.58%), FMR LLC (0.90%), Wasatch Advisors Inc. (0.69%), OxFORD Asset Management LLP (0.64%) and ClariVest Asset Management LLC (0.55%). View Institutional Ownership Trends for MEI Pharma.

Who sold MEI Pharma stock? Who is selling MEI Pharma stock?

MEI Pharma's stock was sold by a variety of institutional investors in the last quarter, including GRT Capital Partners L.L.C., FMR LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for MEI Pharma.

Who bought MEI Pharma stock? Who is buying MEI Pharma stock?

MEI Pharma's stock was purchased by a variety of institutional investors in the last quarter, including ClariVest Asset Management LLC, OxFORD Asset Management LLP, Vanguard Group Inc., JPMorgan Chase & Co., Bank of Montreal Can and Spark Investment Management LLC. View Insider Buying and Selling for MEI Pharma.

How do I buy MEI Pharma stock?

Shares of MEI Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MEI Pharma's stock price today?

One share of MEI Pharma stock can currently be purchased for approximately $2.68.


MarketBeat Community Rating for MEI Pharma (NASDAQ MEIP)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  96 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  164
MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for MEI Pharma (NASDAQ:MEIP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.75 (151.87% upside)

Analysts' Ratings History for MEI Pharma (NASDAQ:MEIP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/26/2017CannReiterated RatingBuy$6.50HighView Rating Details
6/14/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$7.00LowView Rating Details
8/2/2016WedbushReiterated RatingNeutral$2.00N/AView Rating Details
10/7/2015Cowen and CompanyReiterated RatingBuyN/AView Rating Details
9/2/2015Cantor FitzgeraldReiterated RatingBuyN/AView Rating Details
(Data available from 8/20/2015 forward)

Earnings

Earnings History for MEI Pharma (NASDAQ:MEIP)
Earnings by Quarter for MEI Pharma (NASDAQ:MEIP)
Earnings History by Quarter for MEI Pharma (NASDAQ MEIP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q3 2017($0.03)($0.02)$5.00 million$4.51 millionViewN/AView Earnings Details
2/8/2017Q217($0.29)$0.32$1.25 million$17.20 millionViewN/AView Earnings Details
11/8/2016Q1 2017($0.14)($0.12)$0.63 million$1.10 millionViewN/AView Earnings Details
9/6/2016Q4 2016($0.20)($0.17)ViewN/AView Earnings Details
9/2/2015Q4 2015($0.23)($0.17)ViewN/AView Earnings Details
9/9/2014Q4 2014($0.37)($0.40)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for MEI Pharma (NASDAQ:MEIP)
2017 EPS Consensus Estimate: ($0.10)
2018 EPS Consensus Estimate: ($0.57)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20171($0.10)($0.10)($0.10)
Q1 20181($0.12)($0.12)($0.12)
Q2 20181($0.13)($0.13)($0.13)
Q3 20181($0.15)($0.15)($0.15)
Q4 20181($0.17)($0.17)($0.17)
Q1 20191($0.28)($0.28)($0.28)
Q2 20191($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for MEI Pharma (NASDAQ:MEIP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for MEI Pharma (NASDAQ:MEIP)
Insider Ownership Percentage: 4.62%
Institutional Ownership Percentage: 18.03%
Insider Trades by Quarter for MEI Pharma (NASDAQ:MEIP)
Institutional Ownership by Quarter for MEI Pharma (NASDAQ:MEIP)
Insider Trades by Quarter for MEI Pharma (NASDAQ:MEIP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/9/2015Vivo Ventures Vii, LlcMajor ShareholderSell390,572$1.84$718,652.48View SEC Filing  
1/21/2015Charles V Baltic IIIDirectorBuy5,000$3.81$19,050.00View SEC Filing  
12/9/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell79,085$6.01$475,300.85View SEC Filing  
12/8/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell9,004$6.05$54,474.20View SEC Filing  
6/30/2014Charles V Baltic IIIDirectorBuy2,000$6.56$13,120.00View SEC Filing  
10/29/2013Vivo Ventures Vii, LlcMajor ShareholderSell299,609$8.21$2,459,789.89View SEC Filing  
10/2/2013Vivo Ventures Vii, LlcMajor ShareholderSell581,646$10.16$5,909,523.36View SEC Filing  
8/16/2013Charles V Baltic IIIDirectorBuy2,600$6.82$17,732.00View SEC Filing  
6/28/2013Vivo Ventures Vii, LlcMajor ShareholderSell7,337$7.58$55,614.46View SEC Filing  
6/11/2013Vivo Ventures V, LlcMajor ShareholderSell13,727$7.80$107,070.60View SEC Filing  
5/16/2013Vivo Ventures Vii, LlcMajor ShareholderSell17,428$9.07$158,071.96View SEC Filing  
5/8/2013Leaf Ventures Ii L.P. NewMajor ShareholderSell200,000$8.58$1,716,000.00View SEC Filing  
1/25/2013Charles V Baltic IIIDirectorBuy10,200$6.04$61,608.00View SEC Filing  
12/21/2012Charles V Baltic IIIDirectorBuy3,500$7.18$25,130.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for MEI Pharma (NASDAQ:MEIP)
Latest Headlines for MEI Pharma (NASDAQ:MEIP)
Source:
DateHeadline
finance.yahoo.com logoHelsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
finance.yahoo.com - August 3 at 5:05 AM
americanbankingnews.com logoZacks Investment Research Lowers MEI Pharma, Inc. (NASDAQ:MEIP) to Hold
www.americanbankingnews.com - July 23 at 1:19 PM
americanbankingnews.com logoZacks Investment Research Downgrades MEI Pharma, Inc. (NASDAQ:MEIP) to Hold
www.americanbankingnews.com - July 9 at 11:32 PM
nasdaq.com logoMEI Pharma (MEIP) Worth a Look: Stock Rises 12% in Session - Nasdaq
www.nasdaq.com - July 9 at 11:55 AM
americanbankingnews.com logoMEI Pharma, Inc. (MEIP) Receives Buy Rating from Cann
www.americanbankingnews.com - June 26 at 8:34 AM
americanbankingnews.com logoOppenheimer Holdings, Inc. Analysts Give MEI Pharma, Inc. (MEIP) a $7.00 Price Target
www.americanbankingnews.com - June 15 at 10:46 PM
streetinsider.com logoMEI Pharma (MEIP), Helsinn Group Dose First Patient in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in MDS
www.streetinsider.com - June 14 at 9:55 PM
finance.yahoo.com logoOmeros (OMER) Lead Candidate Gets Breakthrough Designation
finance.yahoo.com - June 14 at 9:55 PM
streetinsider.com logoMEI Pharma (MEIP), Helsinn Group Dose First Patient in Phase 2 Dose-Optimization Study of Pracinostat and ... - StreetInsider.com
www.streetinsider.com - June 14 at 9:45 AM
finance.yahoo.com logoHelsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome
finance.yahoo.com - June 14 at 9:45 AM
nasdaq.com logoValeant Inks Deal to Divest iNova Pharmaceuticals for $930M - Nasdaq
www.nasdaq.com - June 13 at 8:00 AM
americanbankingnews.com logoMEI Pharma Inc (MEIP) Short Interest Update
www.americanbankingnews.com - June 11 at 12:46 PM
nasdaq.com logoEndo Asked to Withdraw Pain Drug-Opana ER by FDA, Stock Down - Nasdaq
www.nasdaq.com - June 9 at 11:43 PM
finance.yahoo.com logoMallinckrodt (MNK) Commences Phase III Study of StrataGraft
finance.yahoo.com - June 8 at 7:27 PM
americanbankingnews.com logoBrokers Set Expectations for MEI Pharma Inc's Q4 2017 Earnings (MEIP)
www.americanbankingnews.com - June 8 at 9:18 AM
prnewswire.com logoHelsinn Group and MEI Pharma Report Correlation between ... - PR Newswire (press release)
www.prnewswire.com - June 7 at 6:08 PM
globenewswire.com logoHelsinn Group and MEI Pharma Report Correlation between ... - GlobeNewswire (press release)
globenewswire.com - June 6 at 9:33 AM
finance.yahoo.com logoRadius (RDUS) Announces Positive Data on Breast Cancer Drug
finance.yahoo.com - June 5 at 7:10 PM
americanbankingnews.com logoMEI Pharma Inc (MEIP) Stock Rating Reaffirmed by Cann
www.americanbankingnews.com - June 5 at 4:22 PM
finance.yahoo.com logoHelsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
finance.yahoo.com - June 5 at 9:23 AM
americanbankingnews.com logoMEI Pharma Inc (MEIP) Given a $7.00 Price Target at Oppenheimer Holdings Inc.
www.americanbankingnews.com - June 1 at 11:02 PM
finance.yahoo.com logoNovo Nordisk's (NVO) Drug Gets FDA Approval for Hemophilia B
finance.yahoo.com - June 1 at 7:21 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Catalyst Biosciences and MEI Pharma
finance.yahoo.com - June 1 at 9:27 AM
streetinsider.com logoMEI Pharma (MEIP) Says Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in CCL and ... - StreetInsider.com
www.streetinsider.com - May 31 at 6:53 PM
finance.yahoo.com logoMEI Pharma (MEIP) Shows Strength: Stock Moves 7.6% Higher
finance.yahoo.com - May 30 at 10:06 AM
247wallst.com logoCan MEI Pharma Rise Nearly 300%?
247wallst.com - May 26 at 7:18 PM
americanbankingnews.com logoMEI Pharma Inc (MEIP) Coverage Initiated at Oppenheimer Holdings Inc.
www.americanbankingnews.com - May 25 at 8:51 AM
americanbankingnews.com logoMEI Pharma Inc (MEIP) Now Covered by Analysts at Cann
www.americanbankingnews.com - May 24 at 5:16 PM
finance.yahoo.com logoCatalyst Pharmaceuticals Focuses on Development of Firdapse
finance.yahoo.com - May 23 at 6:00 PM
finance.yahoo.com logoCalithera Biosciences (CALA) Jumps: Stock Moves 17% Higher
finance.yahoo.com - May 22 at 10:11 AM
streetinsider.com logoMEI Pharma (MEIP), Helsinn Group Announce Upcoming Presentations at ASCO - StreetInsider.com
www.streetinsider.com - May 19 at 11:03 AM
finance.yahoo.com logoHelsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
finance.yahoo.com - May 19 at 11:03 AM
finance.yahoo.com logoVertex Ups Kalydeco Sales View as FDA Okays Label Expansion
finance.yahoo.com - May 19 at 11:03 AM
finance.yahoo.com logoReasons to Add Puma Biotechnology (PBYI) to Portfolio Now
finance.yahoo.com - May 17 at 6:28 PM
americanbankingnews.com logoMEI Pharma Inc (MEIP) Raised to "Strong-Buy" at Zacks Investment Research
www.americanbankingnews.com - May 9 at 7:36 AM
americanbankingnews.com logoMEI Pharma Inc (MEIP) Releases Quarterly Earnings Results, Hits Expectations
www.americanbankingnews.com - May 8 at 7:32 PM
prnewswire.com logoMEI Pharma Reports Third Quarter Fiscal Year 2017 Results - PR Newswire (press release)
www.prnewswire.com - May 5 at 8:44 AM
finance.yahoo.com logoMEI Pharma Reports Third Quarter Fiscal Year 2017 Results
finance.yahoo.com - May 4 at 11:44 AM
americanbankingnews.com logoPositive Press Coverage Extremely Likely to Affect MEI Pharma (MEIP) Share Price
www.americanbankingnews.com - April 29 at 11:58 AM
americanbankingnews.com logoMEI Pharma (MEIP) Receiving Very Positive News Coverage, Analysis Finds
www.americanbankingnews.com - April 23 at 8:00 AM
seekingalpha.com logoMEI Pharma (MEIP) Presents At 16th Annual Needham Healthcare Conference - Slideshow
seekingalpha.com - April 7 at 11:10 AM
finance.yahoo.com logo8:02 am MEI Pharma announces appointment of Brian Drazba as CFO
finance.yahoo.com - April 4 at 8:48 AM
biz.yahoo.com logoMEI PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
biz.yahoo.com - April 4 at 8:48 AM
finance.yahoo.com logoMEI Pharma to Present at Needham Healthcare Conference
finance.yahoo.com - March 28 at 10:29 AM
seekingalpha.com logoMEI Pharma (MEIP) Presents At Oppenheimer 27th Annual Healthcare Conference
seekingalpha.com - March 22 at 6:37 PM
finance.yahoo.com logoMEI Pharma to Present at Oppenheimer Healthcare Conference
finance.yahoo.com - March 14 at 11:09 AM
finance.yahoo.com logoMEI PHARMA, INC. Financials
finance.yahoo.com - February 11 at 6:36 PM
bizjournals.com logoMEI Pharma Reports Second Quarter Fiscal Year 2017 Results
www.bizjournals.com - February 8 at 7:18 PM
biz.yahoo.com logoMEI PHARMA, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - February 8 at 7:18 PM

Social

Chart

MEI Pharma (MEIP) Chart for Sunday, August, 20, 2017

This page was last updated on 8/20/2017 by MarketBeat.com Staff